南宁放大型活动心脏发生示教模型宝鸡上肢层次解剖模型,沈阳人体针灸模型 48CM 女性中文塑盘,安徽牙护理保健模型（28颗牙，放大3倍）,浙江2节腰椎带2个病变椎间盘模型,昆明电动医学训练模型,太原一体化椎间孔镜训练模拟器,广西高级全功能老年护理人（男性）

WASHINGTON, April 11 (Xinhua) -- In the first clinical trial of gene therapy for treatment of intractable pain, U.S. researchers from the University of Michigan's Department of Neurology observed that the treatment appears to be able to provide substantial pain relief.In a study published online in the Annals of Neurology and seen on Monday, the researchers showed that the novel agent NP2 is safe and well-tolerated. In addition, measures of pain in the treated patients suggested that NP2 may provide a substantial analgesic effect.NP2 is a gene transfer vector that expresses the naturally- occurring opioid peptide enkephalin. In preclinical work in animals, David Fink, chair of the Department of Neurology, and his coworkers had demonstrated that injection of NP2 into the skin reduces pain in models of pain caused by nerve damage, inflammation or cancer.In the clinical trial, 10 patients with unrelenting pain caused by cancer were injected with the gene transfer agent in the area of skin related to the location of pain."The concept underlying this therapeutic approach is that injection of NP2 into the skin results in uptake into the nervous system and the production and release of a pain-relieving chemical in a controlled site in the pain pathway," says Fink. "In the study, patients who received the low dose of vector showed little reduction in pain; patients receiving the higher doses showed a greater than 80 percent reduction in pain over the course of four weeks following treatment."Fink's laboratory has been working on the use of modified herpes simplex virus-based vectors that are taken up by sensory nerves following skin injection to develop therapies for diseases of the nervous system for more than 20 years. Patents related to this technology have been exclusively licensed by Diamyd Medical, a publicly-traded Swedish biotechnology company that sponsored the trial, and the human-grade vector NP2 was produced by Diamyd, Inc, the U.S. subsidiary of Diamyd Medical.A phase 2 trial to compare NP2 to a placebo control has already been initiated under sponsorship from Diamyd.

BEIJING, May 10 (Xinhuanet) -- Autism spectrum disorder may be under diagnosed and under reported worldwide and rigorous screening is needed for accurate estimates, said researchers in Monday's American Journal of Psychiatry.Researchers from the Yale Child Study Center, George Washington University and other leading institutions screened every child aged 7 to 12 in Ilsan district of the city of Goyang, a community of 488,590 in South Korea, and found more than two-thirds of ASD cases in the mainstream school population unrecognized and untreated.They estimated the prevalence of ASD in South Korea to be 2.64 percent, or approximately 1 in 38 children.The figure is more than twice the rate usually reported in the developed world. Even that rate, about 1 percent, has been climbing rapidly in recent years — from 0.6 percent in the United States in 2007, for example.“From the get-go we had the feeling that we would find a higher prevalence than other studies because we were looking at an understudied population: children in regular schools,” said the lead researcher, Dr. Young-Shin Kim, a child psychiatrist and epidemiologist at the Yale Child Study Center.By contrast, other research groups measure autism prevalence by examining and verifying records of existing cases kept by health care and special education agencies, but leaving out many children whose parents and schools have never sought a diagnosis.Kim said the researchers concluded autism prevalence estimates worldwide may increase if rigorous screening and comprehensive population studies are used to produce prevalence estimates.But it is suggested the findings did not mean that the actual numbers of children with autism were rising, simply that the study was more comprehensive than previous ones.

SAN FRANCISCO, May 10 (Xinhua) -- Microsoft Corp. on Monday said it will buy Internet communications company Skype for 8.5 billion U.S. dollars in cash, a bold move for the software giant to explore new business opportunities."Skype is a phenomenal service that is loved by millions of people around the world," Microsoft CEO Steve Ballmer said in a statement."Together we will create the future of real-time communications so people can easily stay connected to family, friends, clients and colleagues anywhere in the world," he added.Microsoft said it has agreed to buy Skype from the investor group led by Silver Lake, and the deal has been approved by the boards of directors of both companies.Skype will become a new business division within Microsoft, and Skype CEO Tony Bates will assume the title of president of the Microsoft Skype Division, reporting directly to Ballmer.The Skype deal ranks one of the biggest purchase in the 36-year history of Microsoft, which is struggling to compete in the fields of Internet and mobile phones beyond its dominance on personal computer software market.Founded in 2003 and based in Luxembourg, Skype offers a software application that allows users to make free or cheap phone calls and chats over the Internet with additional features including instant messaging and video conferencing.Numbers showed that Skype's 170 million connected users made over 207 billion minutes of voice and video conversations in 2010.Skype was acquired by eBay in September 2005, and then acquired by an investment group led by Silver Lake in November 2009.In a press release announcing the acquisition, Microsoft noted that the deal will increase the accessibility of real-time video and voice communications, generating significant new business and revenue opportunities, and enhancing its existing offerings of real-time communications products and services.Microsoft said Skype will support its devices like Xbox and Kinect, Windows Phone and a wide array of Windows devices, and it will continue to invest in and support Skype clients on non-Microsoft platforms.The acquisition is expected to obtain all required regulatory clearances within this calendar year, Microsoft said.

SAN FRANCISCO, April 18 (Xinhua) -- Apple Inc. has sued Samsung Electronics Co. over patent infringement in a latest suit, U.S. media reported Monday.The suit, filed last Friday in U.S. District Court in Northern California, alleged that Samsung's smartphones, such as "Glaxy S 4G" and "Nexus S," and the Galaxy line of tablet computers violated Apple's patent and trademark, according to All Things Digital, a technology and startup company news site."It's no coincidence that Samsung's latest products look a lot like the iPhone and iPad, from the shape of the hardware to the user interface and even the packaging," the report quoted an Apple representative as saying.Intellectual property suits can be often seen among mobile computing rivals, including suits between Microsoft and Motorola, a suit by Oracle against Google, and Apple's patent dispute with Nokia and HTC.Although Samsung supplies chips for a number of Apple products, Apple CEO Steve Jobs once openly mocked Samsung and other tablet makers as "copycats" during the iPad2 launch. Last month, Apple is reportedly partnering with China's Taiwan Semiconductor Manufacturing Co. to make iPad chips.